Detalles de la búsqueda
1.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 29(14): 1795-1807, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37905526
2.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Mult Scler
; 28(5): 842-846, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882037
3.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler
; 26(1): 48-56, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785358
4.
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Mult Scler
; 26(13): 1729-1739, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31680631
5.
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies.
Mult Scler J Exp Transl Clin
; 9(1): 20552173221142741, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36619856
6.
Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonß-1a versus subcutaneous interferonß-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
BMC Neurol
; 12: 154, 2012 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23216674
7.
Effect of Alemtuzumab Infusions on Vital Signs: A Prospective Observational Study in Patients with Relapsing-Remitting Multiple Sclerosis.
Int J MS Care
; 22(2): 53-59, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32410899
8.
The Effect of a Polysaccharide-Based Multinutrient Dietary Supplementation Regimen on Infections and Immune Functioning in Multiple Sclerosis.
J Diet Suppl
; 17(2): 184-199, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-30285512
9.
The Effect of Broad-Spectrum Dietary Supplementation on Quality of Life, Symptom Severity, and Functioning in Multiple Sclerosis.
J Diet Suppl
; 17(6): 718-732, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31422724
10.
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
CNS Drugs
; 34(9): 973-988, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32710396
11.
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Front Neurol
; 10: 253, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30967831
12.
Safety/tolerability of the anti-semaphorin 4D Antibody VX15/2503 in a randomized phase 1 trial.
Neurol Neuroimmunol Neuroinflamm
; 4(4): e367, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28642891
Resultados
1 -
12
de 12
1
Próxima >
>>